Four competing legislative proposals are moving through the Delaware General Assembly, each offering a different answer to the same unresolved question: who gets to sell intoxicating hemp-derived THC products, under what rules, and at what cost? With the session nearing its close, the debate has exposed a sharp fault line between the state's licensed marijuana industry and the informal hemp retail market that has grown up alongside it - largely unregulated, and increasingly difficult to ignore.
How a Federal Definition Created a Retail Compliance Problem
The origin of the current chaos traces directly to the 2018 U.S. Farm Bill, which defined hemp as cannabis containing 0.3 percent or less THC by dry weight. That definition was intended to open the door for fiber, seed oil, and CBD products. In practice, it also created a pathway for chemically converting CBD into intoxicating compounds - delta-8 THC, delta-9 THC, and others - that technically satisfy the federal threshold at the source plant level while delivering real psychoactive effects in finished products like gummies, vapes, and infused beverages.
Those products are now sold in smoke shops, gas station forecourts, and convenience stores across Delaware. They carry none of the compliance burdens that licensed marijuana dispensaries operate under every day - no seed-to-sale tracking, no mandatory COAs posted at point of sale, no METRC integration, no compliant packaging mandated by the state marijuana commissioner, no age-verification protocols scrutinized by regulators. The Delaware Division of Tobacco and Alcohol Enforcement has already issued 70 cease-and-desist letters to more than 60 businesses for THC product sales - a signal that enforcement interest exists but clear statutory authority does not yet follow.
Two Bills, Two Philosophies on Licensing and Market Access
House Bill 395, introduced by Rep. Nnamdi Chukwuocha, takes the integrationist view: intoxicating hemp products belong inside Delaware's existing marijuana licensing framework, full stop. The bill would broaden the statutory definition of THC to cover chemically derived variants and impose a 0.4-milligram total THC limit per finished product - a threshold aligned with federal language set to take effect in November. Violations involving intoxicating products would generally constitute a Class A misdemeanor, escalating to a Class G felony in circumstances such as proximity to schools or daycares.
That approach has the backing of Delaware Marijuana Commissioner Joshua Sanderlin, who has argued that intoxicating hemp products and regulated marijuana are functionally equivalent at the consumer level and should carry equivalent oversight obligations. Licensed marijuana retailers support this position. Their reasoning is straightforward: they have absorbed the costs of compliant operations - zoning restrictions, security infrastructure, laboratory testing, licensing fees - while watching hemp retailers undercut their retail pricing without bearing comparable overhead.
House Bill 401, sponsored by Rep. Sean Lynn and State Senator Kyra Hoffner, takes a different path. Rather than folding hemp retailers into the marijuana system, it would create a separate licensing lane through the Office of the Marijuana Commissioner specifically for hemp-derived THC products, capped at 10 milligrams per product and limited to adult-use sales to those 21 and older. Gas stations, grocery stores, and convenience stores would be excluded from eligibility. The bill mandates lab testing for potency and contaminants, requires warning labels, and sets packaging standards to limit appeal to minors. A 6 percent state excise tax would apply - significantly lower than the 15 percent excise tax on marijuana sales.
Here's the catch for marijuana operators: that tax differential effectively subsidizes a competitor class. James Brobyn, director of the Delaware Cannabis Industry Association and operator of Field Supply dispensary, has characterized HB 401 as offering an easy, low-cost path that doesn't replicate the burden existing licensees carry. State alcohol and tobacco regulators have raised separate objections - specifically, that HB 401's narrow focus on delta-9 THC could leave regulatory gaps for other intoxicating hemp-derived compounds, and that enforcement authority for their agency remains ambiguous under the bill's current text.
What Operators and Compliance Teams Should Be Watching
For licensed dispensary operators in Delaware - and for multi-state operators with footprints in nearby states facing similar debates - the immediate business implication is a competitive one. If HB 401 or a comparable separate-lane approach passes, hemp retailers gain a form of legitimacy without fully equivalent compliance costs. That affects wholesale pricing pressure, consumer traffic distribution, and the return on investment that licensed operators have made in build-out, security, and compliance infrastructure.
If HB 395 passes, the calculus shifts. Existing hemp retailers would either need to migrate into the marijuana licensing system - absorbing those overhead costs - or exit the intoxicating product market. That outcome could consolidate retail volume back toward licensed dispensaries, but it would also likely trigger legal and political pushback from small business owners who have operated in good faith under the current regulatory ambiguity.
A fourth measure, sponsored separately by Senator Hoffner, addresses a related but distinct problem: clarifying the legal line between hemp-derived products and marijuana under Delaware law. Critically, it would prevent law enforcement from using the mere presence of hemp products as the sole basis for arrest, search, seizure, or criminal prosecution. For retailers operating in the space between these categories - and for their legal counsel - that distinction matters practically, not just philosophically.
The broader pattern is one that compliance professionals in cannabis retail have seen play out in other states: a fast-moving consumer product market outpaces statutory frameworks designed for a different era, and legislators scramble to catch up before the regulatory vacuum becomes too expensive to fill. Delaware is not alone in this. What makes the state's debate notable is the density of competing proposals and the transparency of the commercial interests driving each position.
Whatever framework emerges, operators on both sides of this debate will need to map their SKU inventory, testing protocols, and packaging compliance against whatever statutory definition of THC ultimately prevails. In this space, ambiguity is not a neutral condition. It is an operational risk - and in Delaware right now, that risk is unresolved.
